1.80
+0.04(+2.27%)
Currency In USD
| Previous Close | 1.76 |
| Open | 1.74 |
| Day High | 1.85 |
| Day Low | 1.71 |
| 52-Week High | 3.54 |
| 52-Week Low | 0.66 |
| Volume | 1.76M |
| Average Volume | 1.07M |
| Market Cap | 168.24M |
| PE | -1.06 |
| EPS | -1.7 |
| Moving Average 50 Days | 1.64 |
| Moving Average 200 Days | 1.73 |
| Change | 0.04 |
If you invested $1000 in Caribou Biosciences, Inc. (CRBU) since IPO date, it would be worth $110.29 as of February 21, 2026 at a share price of $1.8. Whereas If you bought $1000 worth of Caribou Biosciences, Inc. (CRBU) shares 3 years ago, it would be worth $294.12 as of February 21, 2026 at a share price of $1.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
GlobeNewswire Inc.
Feb 04, 2026 1:00 PM GMT
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
GlobeNewswire Inc.
Dec 01, 2025 9:05 PM GMT
KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
GlobeNewswire Inc.
Nov 03, 2025 12:00 PM GMT
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vis